🔎 Trials Near Me

Akèy › Kansè nan tete › Iowa

Etid klinik pou Kansè nan tete nan Iowa

22 etid pou Kansè nan tete ap chèche patisipan nan sit nan Iowa.

Vil nan Iowa

Tèks ofisyèl etid la (Anglè)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mary Greeley Medical Center, Ames
  • McFarland Clinic - Ames, Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • ak 12 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

  • Accellacare of McFarland, Ames
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • University of Iowa Hospitals and Clinics, Iowa City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • Local Institution - 0065, Iowa City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06618287

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • University of Iowa, Iowa City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Mission Cancer and Blood, Des Moines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

  • University of Iowa Hospitals and Clinics, Iowa City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06756932

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Mary Greeley Medical Center, Ames
  • McFarland Clinic - Ames, Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • ak 17 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • University of Iowa, Iowa City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399

Exercise Oncology Clinic Pilot Feasibility Trial

  • University of Iowa Health Care, Iowa City
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07765927

Breast Cancer PSMA PET

  • University of Iowa Healthcare, Iowa City
Ap rekriteFaz 1 bonè
Laj 18 a 90 · Fanm · Mizajou Aug 6, 2026 · NCT06586047

E-Mindfulness Approaches for Living After Breast Cancer

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf
  • Saint Anthony Regional Hospital, Carroll
  • ak 10 plis
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • University of Iowa, Iowa City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

  • Iowa Holden Comprehensive Cancer Center, Iowa City
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT06169371

Integrated Cancer Repository for Cancer Research

  • Methodist Jennie Edmundson Hospital, Council Bluffs
  • Covenant Medical Center, Inc, Waterloo
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • University of Iowa Health Care, Iowa City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05283330

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • Mary Greeley Medical Center, Ames
  • McFarland Clinic - Ames, Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • ak 11 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887

Quantitative MRI Assessment of Breast Cancer Therapy Response

  • University of Iowa, Iowa City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT05704062

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf
  • Physicians' Clinic of Iowa PC, Cedar Rapids
  • ak 10 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Iowa City
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • Medical Oncology and Hematology Associates-West Des Moines, Clive
  • Mercy Cancer Center-West Lakes, Clive
  • Mercy Medical Center - Des Moines, Des Moines
  • ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.